Evogene

Company Overview

Snapshot

Founded in January 2002 by Rafi Meissner and Hagai Karchi, Evogene operates with 51–200 employees. The company has raised a total of $135.7 million across 10 funding rounds from 9 investors. In November 2013, Evogene went public on NASDAQ, following its public listing on TASE in June 2007.

Business overview

Evogene is a computational biology company that leverages its broadly applicable computational predictive biology (CPB) platform to revolutionize product discovery and development across various life sciences-based industries, including human health and agriculture. The CPB platform integrates a deep understanding of biology with big data and artificial intelligence to computationally discover and guide the development of life sciences products based on microbes, small molecules, and genetic elements. Through its subsidiaries, Evogene is advancing product pipelines for human microbiome-based therapeutics, medical cannabis, agricultural biologicals, agriculture chemicals, and agriculture solutions for castor oil production.

Strategic signal

In October 2024, Evogene announced a collaboration with Google Cloud to develop a generative AI foundation model for novel small molecule design. This partnership signals a significant strategic move into advanced AI applications, potentially accelerating drug discovery and chemical development processes, and demonstrating the company's commitment to leveraging cutting-edge technology to enhance its computational predictive biology platform.

Company Intelligence Q&A

What was a significant recent collaboration for Evogene?

In October 2024, Evogene announced a collaboration with Google Cloud to pioneer a generative AI foundation model for novel small molecule design, aiming to revolutionize product discovery in life sciences.

What recent grant did Lavie Bio, an Evogene subsidiary, receive?

In September 2024, Lavie Bio received a grant from the Israel Innovation Authority to advance the development of 'MicroFermentor', a technology designed to improve the economics of ag-biologicals.

What was a key operational milestone for Casterra, an Evogene subsidiary, in Africa?

In October 2024, Casterra announced the completion of its first shipment of castor seeds grown and processed in Kenya, marking a key milestone in its operational expansion plan in Africa.

What was the outcome of Lavie Bio's bio-fungicide program against downy mildew?

In November 2023, Lavie Bio reported advancement in its bio-fungicide program against downy mildew, with successful 2023 field trial results.

When did Evogene go public on NASDAQ?

Evogene went public on NASDAQ in November 2013, raising $74 million with a valuation of $355 million.